Funding
← Back to your selection

UPMC Enterprises

Activity from announced rounds

Activity in this selectionSeries A

UPMC Enterprises is the organization identified in its own RAAPID, BrainCheck and ai3Bio materials.

Recorded funding activity

RAAPID supplies healthcare risk-adjustment software. Ai3Bio develops immune-cell-targeted medicines. The pending ai3Bio relation stays in draft, and the organization remains separate from UPMC and the University of Pittsburgh.

Sources
Rounds participated in
4
Confirmed lead rounds
1
2 roles undisclosed
New companies
4
First participation on record · 0 follow-on
Funding in participating rounds
$154M
3 disclosed · full round size, not this investor’s share

By stage

Series A4

By primary sector

Biotech2
Healthtech2

By country

United States4

Rounds

4 in this selection
Estuary Biotherapeutics

Estuary Biotherapeutics develops locally delivered gene therapies for patients with inherited polycystic kidney disease.

$93MSeries A
Participant
ai3Bio

ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.

$48MSeries A
Lead
RAAPID

Provides AI-powered risk adjustment solutions for healthcare

UndisclosedSeries A+
Role not disclosed
BrainCheck

Provides digital cognitive assessment and care for healthcare organizations

$13MSeries A
Role not disclosed